In 2025 BioMark Diagnostics Inc. (OTCQB: BMKDF) advanced its position as a global leader in liquid biopsy technologies for early cancer detection. The company scaled its laboratory throughput twofold, completing Canada’s largest lung cancer diagnostic study of over 7,000 patients and securing exclusive partnership status in the 10,000-patient HANSE trial—the largest prospective lung cancer study since 2013. Regulatory milestones included submission of ISO 15189 certification documents in December, paving the way for U.S. CLIA and CAP accreditation. Scientific accomplishments featured six peer-reviewed publications in high-impact journals and recognition with the CQDM Innovation Prize. On the funding front, BioMark raised $4.5 million in growth capital, secured Horizon Europe research grants, Manitoba Lung Association support for a First Nations pilot program, and City of Québec funding—diversifying revenue pathways and strengthening its commercial and clinical validation pipeline. For 2026, key catalysts include obtaining ISO accreditation, filing CLIA/CAP applications, publishing HANSE trial data, negotiating industry licensing, launching ISO-certified laboratory services and expanding distribution channels, all underpinned by targeted hires in patient engagement, revenue generation, data science and regulatory affairs.

On December 30, 2025, BioMark added technology investor and AI strategist James Lavender to its Board of Directors. Lavender, a lead investor in BioMark’s March financing, brings extensive enterprise software development and AI/ML scaling expertise. He has facilitated high-level introductions with U.S. state regulatory bodies and strategic investment groups, directly supporting the company’s transition from R&D into commercial execution. His guidance will be instrumental as BioMark finalizes U.S. certifications, expands its lab services footprint and advances reimbursement negotiations with payors and screening centers—critical steps in capturing an addressable market of over 16 million at-risk individuals requiring annual lung cancer screening.